Table 2.
Contemporary clinical studies assessing the therapeutic and immunological characteristics of cyclophosphamide.
| Indication(s) | Phase | Status | Notes | Ref. |
|---|---|---|---|---|
| B cell lymphoma | II | Recruiting | Combined with pembrolizumab and DPX-survivax | NCT03349450 |
| Breast cancer | I | Withdrawn | Combined with doxorubicin and glembatumumab vedotin | NCT03473691 |
| I/II | Recruiting | Combined with SV-BR-GM, pembrolizumab and interferon inoculation | NCT03328026 | |
| II | Recruiting | Combined with doxorubicin, nivolumab and ipilimumab | NCT03409198 | |
| Not yet recruiting | Combined with multimodal chemotherapy, pertuzumab, atezolizumab, trastuzumab emtansine and surgical resection | NCT03894007 | ||
| Recruiting | Combined with epirubicin, nab-paclitaxel and pembrolizumab | NCT03289819 | ||
| Recruiting | Combined with multimodal chemotherapy and pembrolizumab | NCT03515798 | ||
| III | Recruiting | Combined with multimodal chemotherapy and atezolizumab | NCT03197935 | |
| NA | Recruiting | Combined with doxorubicin and alpha lipoic acid | NCT03908528 | |
| Gastroesophageal cancer | I/II | Recruiting | Combined with pembrolizumab and IRX-2 | NCT03918499 |
| Glioma | I | Recruiting | Combined with fludarabine, temozolomide, TTRNA-DC vaccine with GM-CSF, TTRNA-xALT, autologous HSC and Td vaccine | NCT03396575 |
| Withdrawn | Combined with fludarabine, GINAKIT cells | NCT02439788 | ||
| I/II | Recruiting | Combined with surgical resection and lysate-loaded dendritic cell vaccine | NCT03879512 | |
| II | Recruiting | Combined with multimodal chemotherapy, ASCT, EBRT, sargrasmostim, dinutuximab and aldesleukin | NCT03786783 | |
| Hematological malignancies | I | Recruiting | Combined with multimodal chemotherapy, total body irradiation and cord blood stem cells | NCT03885947 |
| Not yet recruiting | Combined with fludarabine and CAR-aNKT cells | NCT03774654 | ||
| I/II | Recruiting | Combined with fludarabine, ALLO-501 and ALLO-647 | NCT03939026 | |
| Withdrawn | Combined with GM-CSF and TAPA-pulsed DC vaccine | NCT02223312 | ||
| Active, not recruiting | Combined with GM-CSF and TAPA-pulsed DC vaccine | NCT02709993 | ||
| II | Recruiting | Combined with fludarabine and axicabtagene ciloleucel | NCT03761056 | |
| Recruiting | Combined with multimodal chemotherapy, nivolumab and rituximab | NCT03749018 | ||
| n.s | Recruiting | Combined with cord blood transplantation | NCT03802773 | |
| Leukemia | I | Recruiting | NCT03241940 | |
| Recruiting | Combined with fludarabine phosphate and CD19/CD22 CAR-T cell therapy | NCT03233854 | ||
| Not yet recruiting | Combined with fludarabine, CD19 CAR-T cells and PD-1 KO engineered T cells | NCT03298828 | ||
| Recruiting | Combined with tacrolimus, allogeneic HSC transplantation, filgrastim and total marrow irradiation | NCT03467386 | ||
| Recruiting | Combined with fludarabine and omnlmmune | NCT03790072 | ||
| Recruiting | Combined with leukapheresis, fludarabine and huJCAR014 | NCT03103971 | ||
| Recruiting | Combined with fludarabine and anti-CD19/CD22 CAR-T cells | NCT03919526 | ||
| I/II | Recruiting | Combined with fludarabine and KTE-X19 | NCT03624036 | |
| III | Recruiting | Combined with multimodal chemotherapy, TBRT, G-CSF and peripheral blood transplant | NCT03480360 | |
| NA | Recruiting | Combined with multimodal chemotherapy, thymoglobuline, cyclosporine, lymphocyte injection of prophylactic donor and transfusion graft of peripheral stem cells | NCT03035422 | |
| Liver cancer | I | Recruiting | Combined with nivolumab and IRX-2 | NCT03655002 |
| Active, not recruiting | Combined with fludarabine and GAP-T cells | NCT02932956 | ||
| I/II | Recruiting | Combined with IMA970A and CV8102 | NCT03203005 | |
| Recruiting | Combined with fludarabine and MUC-1 CAR-T cells | NCT03633773 | ||
| II/III | Recruiting | Combined with iNKT cells and human recombinant IL-2 | NCT04011033 | |
| Lung cancer | I | Recruiting | Combined with radiation, G-CSF and PBMCs | NCT02579005 |
| Not yet recruiting | Combined with fludarabine and PD-L1 CAR-T cells | NCT03330834 | ||
| Melanoma | I | Recruiting | Combined with fludarabine, IL-2, nivolumab and adoptive transfer of autologous TILs | NCT03475134 |
| Recruiting | Combined with fludarabine, autologous TILs, aldesleukin, nivolumab and ipilimumab | NCT03526185 | ||
| Myeloid malignancies | II | Not yet recruiting | Combined with multimodal chemotherapy cyclosporine, tacrolimus and HSC transplantation | NCT03270748 |
| Myeloma | I | Recruiting | Combined with fludarabine and SLAMF7 CAR-T therapy | NCT03710421 |
| Recruiting | Combined with fludarabine, gamma secretase inhibitor LY3039478, BCMA specific CAR-T cells | NCT03502577 | ||
| Recruiting | Combined with fludarabine, BCMA CART and huCAR-T19, | NCT03549442 | ||
| Recruiting | Combined with fludarabine and CAR-BCMA T cells | NCT03716856 | ||
| NA | Recruiting | Combined with fludarabine and CAR-BCMA T cells | NCT03380039 | |
| Osteosarcoma | II | Recruiting | Combined with fludarabine, fludarabine phosphate, aldesleukin and TILs | NCT03449108 |
| Ovarian cancer | I | Recruiting | Combined with decitabine, aldesleukin, genetically engineered NY-ESO 1 specific T lymphocytes | NCT03017131 |
| Recruiting | Combined with fludarabine and anti-meso CAR-T cells | NCT03799913 | ||
| II | Withdrawn | Combined with anti-CSF1 mAb PD-0360324 | NCT02948101 | |
| Pancreatic cancer | I | Recruiting | Combined with GVAX, pembrolizumab and IMC-CS4 | NCT03153410 |
| Prostate cancer | I | Recruiting | Combined with fludarabine, fludarabine phosphate and autologous anti-PSCA-CAR-T-cells | NCT03873805 |
| Sarcoma | II | Withdrawn | Combined with pembrolizumab, GSK3377794 and fludarabine | NCT03697824 |
| Solid and hematological malignancies | I/II | Recruiting | Combined with CAR-T cell therapy | NCT03638206 |
| Solid malignancies | I | Withdrawn | Combined with GM-CSF and TAPA-pulsed DC vaccine | NCT02705703 |
| Recruiting | Combined with RT, aspirin, nivolumab and ipilimumab | NCT03728179 | ||
| I/II | Recruiting | Combined with fludarabine and PD-1 expressing mesoCAR-T cells | NCT03615313 | |
| Active, not recruiting | Combined with imiquimod topical cream and TAPA-pulsed DC vaccine | NCT02224599 | ||
| II | Recruiting | Combined with pembrolizumab and DPX-survivax | NCT03836352 |
ALLO, allogeneic; ASCT, autologous hematopoietic stem cell transplantation; CAR-aNKT cells, CAR allogeneic natural killer T cells; CAR, chimeric antigen receptor; DC, dendritic cell; CSF-1, colony stimulating factor 1; EBRT, external beam radiation therapy; GAP, glypican 3; GINAKIT cells, GD2-specific CAR- and interleukin 15- expressing autologous NKT cells; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSC, hematopoietic stem cell; IL, interleukin; mAb, monoclonal antibody; Meso-CAR-T cells, mesothelin-redirected chimeric antigen receptor T cell; iNKT cells, invariant NKT cells; KO, knock-out; NA, not applicable; NS, not specified; PBMC, peripheral blood mononuclear cell; PSC, pluripotent stem cells; RT, radiotherapy; TAPA, tumor-associated peptide antigen; TBRT, total body RT; TD, Tetanus-Diphtheria; TIL, tumor-infiltrating lymphocyte; TTRNA, total tumor RNA; xALT, autologous lymphocyte transfer.